Carnegie Capital Asset Management LLC Purchases 4,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Carnegie Capital Asset Management LLC lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 17.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,400 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in Iovance Biotherapeutics were worth $223,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in IOVA. Lazard Asset Management LLC boosted its position in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 934 shares during the period. Baird Financial Group Inc. boosted its position in Iovance Biotherapeutics by 3.7% during the first quarter. Baird Financial Group Inc. now owns 27,545 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 995 shares during the period. Rockefeller Capital Management L.P. boosted its position in Iovance Biotherapeutics by 3.8% during the second quarter. Rockefeller Capital Management L.P. now owns 37,758 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 1,385 shares during the period. Diversified Trust Co boosted its position in Iovance Biotherapeutics by 12.3% during the fourth quarter. Diversified Trust Co now owns 13,512 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 1,481 shares during the period. Finally, American Century Companies Inc. lifted its holdings in shares of Iovance Biotherapeutics by 0.5% during the first quarter. American Century Companies Inc. now owns 319,310 shares of the biotechnology company’s stock worth $1,951,000 after buying an additional 1,649 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Stock Down 1.0 %

IOVA stock opened at $11.80 on Thursday. The business has a 50-day simple moving average of $13.77 and a 200 day simple moving average of $8.84. Iovance Biotherapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $1.44 million. During the same period in the previous year, the business posted ($0.64) earnings per share. As a group, research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Truist Financial reissued a “buy” rating and set a $17.00 target price on shares of Iovance Biotherapeutics in a report on Wednesday, December 27th. The Goldman Sachs Group lifted their target price on Iovance Biotherapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. StockNews.com raised Iovance Biotherapeutics to a “sell” rating in a report on Friday, February 2nd. Chardan Capital lifted their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, February 20th. Finally, Piper Sandler lifted their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. According to MarketBeat, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $24.64.

Insiders Place Their Bets

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was purchased at an average price of $9.15 per share, with a total value of $2,287,500.00. Following the completion of the purchase, the director now owns 320,150 shares in the company, valued at $2,929,372.50. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 10.40% of the company’s stock.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.